BioResearch

Lonza

Amaxa™ HT Nucleofector™ Basic Protocol for Primary Mammalian Smooth Muscle Cells (SMC)

Cell Description

Cells derived from mammalian smooth muscle cell tissues from various organs; adherent long tapering cells.

Note

Mammalian smooth muscle cells display significant phenotypic variations due to the wide range of both species and tissues from which they may be sourced.

This basic protocol describes how to easily define optimal Nucleofection™ conditions for different mammalian smooth muscle cells. We recommend to first test a set of pre-selected Nucleofector™ programs together with the P1 primary cell HT Nucleofector™ kit.

If you have questions regarding your epithelial cells of interest, please contact our scientific support team for further help with the optimization.

Product Description

Recommended Kits

P1 primary cell HT Nucleofector™ Kits

Cat. No.	V5SP-1002
Size (reactions)	2×384
P1 primary cell HT Nucleofector™ solution	22.5 ml
Supplement	5 ml
pmaxGFP™ vector (1.0 µg/µl in 10 mM Tris pH 8.0)	50 µg
384-well Nucleocuvette™ plate(s)	2

Cat. No.	V5SP-1010
Size (reactions)	10×384
P1 primary cell HT Nucleofector™ solution	90 ml
Supplement	20 ml
pmaxGFP™ vector (1.0 µg/µl in 10 mM Tris pH 8.0)	150 µg
384-well Nucleocuvette™ plate(s)	10

Storage and Stability

Store Nucleofector™ solution, supplement and pmaxGFP™ vector at 4°C. For long term storage pmaxGFP™ vector is ideally stored at -20°C. The expiry date is printed on the solution box. Once the Nucleofector™ supplement is added to the Nucleofector™ solution it is stable for three months at 4°C.

Note

HT Nucleofector™ solutions can only be used with conductive polymer cuvettes, i.e. in the HT Nucleofector™, the well Shuttle™ device and in the 4D-Nucleofector™ system. They are not compatible with the Nucleofector™ II/2b device.

Optimization Guidelines

The initial optimization experiment is comprised of 14 reactions, using 1 Nucleocuvette™ plate: 6 different Nucleofector™ programs are tested in duplicate plus 1 control. The Nucleofection™ condition which turns out to be the most appropriate should be used for all subsequent transfections.

	1×10^5 cells/sample		
	1	2	3–12
A	FF-130-AA	FF-130-AA	—
B	FG-113-AA	FG-113-AA	—
C	DS-137-AA	DS-137-AA	—
D	CM-137-AA	CM-137-AA	—
E	EH-106-AA	EH-106-AA	—
F	FP-113-AA	FP-113-AA	—
G	negative control (no program)	negative control (no program)	—
H	—	—	—

The P1 primary cell HT Nucleofector™ kit has been tested successfully for the following Clonetics™ primary cells provided by Lonza:

Cell type	Lonza Cat. No.	Optimal program	Transfection efficiency	Viability*
AoSMC (human aortic smooth muscle cells)	CC-2571	EH-106-AA	74 %	92 %
CASMC (human coronary artery smooth muscle cells)	CC-2583	FP-113-AA	67 %	86 %
PASMC (human pulmonary artery smooth muscle cells)	CC-2581	FG-113-AA	81 %	67 %

*Determined by ViaLight™ Plus Kit, Lonza

Required Material

Note
Please make sure that the entire supplement is added to the Nucleofector™ solution.

- Nucleofector™ System
- Supplemented HT Nucleofector™ solution at room temperature for Nucleofection™
- Supplied 384-well Nucleocuvette™ plate(s)
- Supplied pmaxGFP™Vector, stock solution 1 µg/µl

Note
Volume of substrate solution added to each sample should not exceed 10 % of the total reaction volume (2 µl for 20 µl reactions). For positive control using pmaxGFP™ vector, please dilute the stock solution to reach the appropriate working concentration.

- Substrate of interest, highly purified, preferably by using endotoxin free kits; A260 : A280 ratio should be at least 1.8
- 384-well Nucleocuvette™ plates are best handled with an automated liquid handling system. If manual pipetting is required please use compatible tips: epT.I.P.S. [US/CDN: Eppendorf North America, Cat. No. 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266], Matrix TallTips™ [Matrix Technologies Corp., Cat. No. 7281] or LTS Tips [Rainin Instrument, LLC, Cat. No. SR-L10F, SR/SS-L250S, SR/SS-L300S]. Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette™ wells without getting stuck
- 384-well culture plates or culture plates of your choice
- For trypsinization: Please use trypsin as recommended by the cell supplier e.g. ReagentPack™ Subculture Reagent Kit containing Trypsin/EDTA, HEPES Buffered Saline Solution (HEPES-BSS) and Trypsin Neutralizing Solution (TNS) [Lonza; Cat. No. CC-5034]
- Culture medium: Please use media as recommended by the cell supplier e.g. SmGM™-2 BulletKit™ [Lonza; Cat. No. CC-3182]
- Prewarm appropriate volume of culture media at 37°C (140 µl per sample)
- Appropriate number of cells (1×10^5 cells per sample; minimal cell number: 5×10^4 cells; a lower cell number may lead to a major increase in cell mortality)

1. Pre Nucleofection™

Note
Transfection results may be cell-source dependent.

Cell Culture Recommendations

1.1 Replace medium every 1–3 days
1.2 Cells should be passaged after reaching 70–80 % confluency
1.3 Do not use cells after passage 9 for Nucleofection™ as this may lead to reduced viability and transfection efficiency
1.4 Cells should be passaged 2–4 days before Nucleofection™ depending on growth rate of cells

Note
Culture conditions may differ between cell types. Please follow your established procedure or the supplier's recommendations.

Trypsinization

Note
Please follow your established procedure or the supplier's recommendations (e.g. for Aortic Smooth Muscle Cells [Lonza; Cat. No. CC-2571] follow procedure described below).

1.5 Remove media from the cultured cells and wash cells once with HEPES-BSS
1.6 For harvesting, incubate the cells ~5 minutes at 37°C with recommended volume of indicated trypsinization reagent (please see required material)
1.7 Inactivate trypsin with TNS once the majority of the cells (>90 %) have been detached

2. Nucleofection™

One Nucleofection™ Sample Contains

- 1×10^5 cells
- 0.2–0.4 µg plasmid DNA (in 1–2 µl H_2O or TE) or 0.2 µg pmaxGFP™ vector or 30–300 nM siRNA (0.6–6 pmol/sample)
- 20 µl P1 primary cell HT Nucleofector™ solution

2.1 Please make sure that the entire supplement is added to the Nucleofector™ solution
2.2 Start HT Nucleofector™ software, verify device connection and upload experimental parameter file (for details refer to the HT Nucleofector™ Manuals)
2.3 Select appropriate HT Nucleofector™ program. Please try all 6 Nucleofector™ Programs (**FF-130, FG-113, DS-137, CM-137, EH-106 and FP-113**) initially to determine the most appropriate Nucleofection™ condition for your specific smooth muscle cell type

2.4 Prepare cell culture plates by filling the appropriate number of wells with the desired volume of the recommended culture media, e.g. 88 µl* (see note at the end of this chapter) for one well of a 96-well plate, and pre-incubate/equilibrate plates in a humidified 37°C/5 % CO_2 incubator

2.5 Pre-warm an aliquot of culture media to 37°C (40 µl* per sample)

2.6 Prepare 0.2–0.4 µg plasmid DNA or 0.2 µg pmaxGFP™ vector (recommended for initial optimization). For siRNA experiments we re-commend to start using 30–300 nM siRNA (0.6–6 pmol/sample)

2.7 Harvest the cells by trypsinization (please see 1.5–1.7)

2.8 Count an aliquot of the trypsinized cells and determine cell density

2.9 Centrifuge the required number of cells (1×10^5 cells per sample) at 100×g for 10 minutes at room temperature

2.10 Resuspend the cell pellet carefully at room temperature using 20 µl HT Nucleofector™ solution per sample

A: One or several substrates (DNAs or RNAs) in multiples

– Prepare mastermixes by dividing cell suspension according to number of substrates
– Add required amount of substrates to each aliquot (max. 2 µl per sample)
– Transfer 20 µl of mastermixes into the wells of the 384-well Nucleocuvette™ plates

B: Multiple substrates (e.g. library transfection)

– Pipette 20 µl of cell suspension into each well of a sterile U-bottom 384-well microtiter plate
– Add 2 µl substrates (maximum) to each well
– Transfer 20 µl of cells with substrates into the wells of the 384-well Nucleocuvette™ plates

Note

It is advisable to pre-dispense each cell suspension into a sterile round-bottom 384-well plate or to pipet from a pipetting reservoir for multi-channel pipettes. Use a liquid handling system or at least a multi-channel pipette with suitable pipette tips. As leaving cells in HT Nucleofector™ solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

2.11 Briefly shake the 384-well Nucleocuvette™ plate with an appropriate microtiter plate shaker to make sure the sample covers the bottom and the sides of the wells without air bubbles. Alternatively thoroughly tap the 384-well Nucleocuvette™ plate

2.12 Place 384-well Nucleocuvette™ plate with closed lid onto the carousel of the plate handler of the HT Nucleofector™. Well "A1" must be in upper left position

2.13 Start Nucleofection™ process clicking "Start" in the HT Nucleofector™ software (for details refer to the HT Nucleofector™ Manuals)

2.14 After run completion, carefully remove the 384-well Nucleocuvette™ plate from the carousel

2.15 Resuspend cells with desired volume of pre-warmed culture medium (maximum cuvette volume 60 µl). Mix cells by gently pipetting up and down two to three times. Recommendation for 96-well plates: Resuspend cells in 40 µl of pre-warmed media*

2.16 Plate desired amount of cells in culture system of your choice. Recommendation for 96-well plates: Transfer 12 µl of resuspended cells to 88 µl pre-warmed media

Note

The indicated plating cell numbers and volumes produce optimal Nucleofection™ results in most cases. However, you may wish to test an extended range of cell numbers depending on your specific needs. Cell numbers and volumes can be adapted such that fewer cells are transferred or duplicate plates can be seeded.

3. Post Nucleofection™

3.1 Incubate the plating cells in a humidified 37°C/5 % CO_2 incubator until analysis. Gene expression or down- regulation, is often detectable after only 4–8 hours. To validate optimal conditions for down regulation we recommend performing a time course experiment

Additional Information

Up-to-date List of all Nucleofector™ References

www.lonza.com/nucleofection-citations

Technical Assistance and Scientific Support

USA/Canada
Tel 800 521 0390 (toll-free)
Fax 301 845 8338
scientific.support@lonza.com

Europe and Rest of World
Tel +49 221 99199 400
Fax +49 221 99199 499
scientific.support.eu@lonza.com

www.lonza.com

Lonza Cologne GmbH–50829 Cologne, Germany

Please note that the Amaxa™ Nucleofector™ technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector™ technology, comprising Nucleofection™ process, Nucleofector™ device, Nucleofector™ solutions, Nucleofector™ 96-well Shuttle™ system, 96-well Nucleocuvette™ plates and modules , HT Nucleofector™ and 384-well Nucleocuvette™ plates is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH. Amaxa, Nucleofector, Nucleofection, well Shuttle, Nucleocuvette, maxGFP, Clonetics, Reagent Pack, SmGM and BulletKit are either registered trademarks or trademarks of the Lonza Group or its affiliates. TallTips are a registered trademark of Matrix Technologies Corporation. Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com. The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242. The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license. No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2009, Lonza Cologne GmbH. All rights reserved–D5SP-9015 2011-07